[1]
|
Kamstrup, P.R. (2021) Lipoprotein(A) and Cardiovascular Disease. Clinical Chemistry, 67, 154-166.
https://doi.org/10.1093/clinchem/hvaa247
|
[2]
|
Tsimikas, S. and Marcovina, S.M. (2022) Ancestry, Lipoprotein(A), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week. Journal of the American College of Cardiology, 80, 934-946.
https://doi.org/10.1016/j.jacc.2022.06.019
|
[3]
|
Chemello, K., Chan, D.C., Lambert, G., et al. (2022) Recent Ad-vances in Demystifying the Metabolism of Lipoprotein(A). Atherosclerosis, 349, 82-91. https://doi.org/10.1016/j.atherosclerosis.2022.04.002
|
[4]
|
Chiesa, G., Zenti, M.G., Baragetti, A., et al. (2023) Consensus Document on Lipoprotein(A) from the Italian Society for the Study of Atherosclerosis (SISA). Nutrition, Metabolism and Cardiovascular Diseases, 33, 1866-1877.
https://doi.org/10.1016/j.numecd.2023.07.019
|
[5]
|
北京心脏学会. 脂蛋白(A)与心血管疾病风险关系及临床管理的专家科学建议[J]. 中国循环杂志, 2021, 36(12): 1158-1167.
|
[6]
|
Kronenberg, F., Mora, S., Stroes, E.S.G., et al. (2022) Lipoprotein(A) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis: A European Atherosclerosis Soci-ety Consensus Statement. European Heart Journal, 43, 3925-3946.
https://doi.org/10.1093/eurheartj/ehac361
|
[7]
|
Pearson, G.J., Thanassoulis, G., Anderson, T.J., et al. (2021) 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Canadian Journal of Cardiology, 37, 1129-1150. https://doi.org/10.1016/j.cjca.2021.03.016
|
[8]
|
王增武, 刘静, 李建军, 等. 中国血脂管理指南(2023年) [J]. 中国循环杂志, 2023, 38(3): 237-271.
|
[9]
|
Simantiris, S., Antonopoulos, A.S., Papastamos, C., et al. (2023) Lipoprotein(A) and Inflammation-Pathophysiological Links and Clinical Implications for Cardiovascular Disease. Journal of Clinical Lipidology, 17, 55-63.
https://doi.org/10.1016/j.jacl.2022.10.004
|
[10]
|
Bhatia, H.S., Becker, R.C., Leibundgut, G., et al. (2023) Lipopro-tein(A), Platelet Function and Cardiovascular Disease. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-023-00947-2
|
[11]
|
Liu, H.H., Cao, Y.X., Jin, J.L., et al. (2020) Association of Lip-oprotein(A) Levels with Recurrent Events in Patients with Coronary Artery Disease. Heart, 106, 1228-1235. https://doi.org/10.1136/heartjnl-2020-316586
|
[12]
|
Cui, K., Yin, D., Zhu, C., et al. (2022) How Do Lipoprotein(A) Concentrations Affect Clinical Outcomes for Patients with Stable Coronary Artery Disease Who Underwent Different Dual Antiplatelet Therapy after Percutaneous Coronary Intervention? Journal of the American Heart Association, 11, e023578. https://doi.org/10.1161/JAHA.121.023578
|
[13]
|
Gilliland, T.C., Liu, Y., Mohebi, R., et al. (2023) Lipo-protein(A), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes. Journal of the American College of Cardiology, 81, 1780-1792.
https://doi.org/10.1016/j.jacc.2023.02.050
|
[14]
|
Ong, K.L., Mcclelland, R.L., Allison, M.A., et al. (2021) Lipopro-tein(A) and Coronary Artery Calcification: Prospective Study Assessing Interactions with Other Risk Factors. Metabo-lism, 116, Article ID: 154706.
https://doi.org/10.1016/j.metabol.2021.154706
|
[15]
|
Kaiser, Y., Daghem, M., Tzolos, E., et al. (2022) Association of Lipoprotein(A) with Atherosclerotic Plaque Progression. Journal of the American College of Cardiology, 79, 223-233. https://doi.org/10.1016/j.jacc.2021.10.044
|
[16]
|
Yu, Q., Xue, Q., Liu, H., et al. (2023) Impact of Low-Density Lip-oprotein Cholesterol and Lipoprotein(A) on Mid-Term Clinical Outcomes Following Coronary Artery Bypass Grafting: A Secondary Analysis of the DACAB Trial. Frontiers in Cardiovascular Medicine, 10, Article ID: 1103681. https://doi.org/10.3389/fcvm.2023.1103681
|
[17]
|
Jin, J.L., Zhang, H.W., Liu, H.H., et al. (2022) Lipoprotein(A) and Cardiovascular Outcomes in Patients with Coronary Artery Disease and Different Metabolic Phenotypes. Frontiers in Cardiovascular Medicine, 9, Article ID: 870341.
https://doi.org/10.3389/fcvm.2022.870341
|
[18]
|
(2023) Chinese Guidelines on Diagnosis and Management of Atrial Fibrillation. Chinese Journal of Cardiology, 51, 572-618.
|
[19]
|
Singh, S., Baars, D.P., Desai, R., et al. (2023) Associa-tion between Lipoprotein (A) and Risk of Atrial Fibrillation: A Systematic Review and Meta-Analysis of Mendelian Randomization Studies. Current Problems in Cardiology, 49, Article ID: 102024. https://doi.org/10.1016/j.cpcardiol.2023.102024
|
[20]
|
Mohammadi-Shemirani, P., Chong, M., Narula, S., et al. (2022) Elevated Lipoprotein(A) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study. Journal of the American College of Cardiology, 79, 1579-1590.
https://doi.org/10.1016/j.jacc.2022.02.018
|
[21]
|
Ding, W.Y., Protty, M.B., Davies, I.G., et al. (2022) Relationship between Lipoproteins, Thrombosis, and Atrial Fibrillation. Cardiovascular Research, 118, 716-731. https://doi.org/10.1093/cvr/cvab017
|
[22]
|
Zheng, K.H., Tsimikas, S., Pawade, T., et al. (2019) Lipoprotein(A) and Oxidized Phospholipids Promote Valve Calcification in Patients with Aortic Stenosis. Journal of the American College of Cardiology, 73, 2150-2162.
https://doi.org/10.1016/j.jacc.2019.01.070
|
[23]
|
Tao, J., Yang, X., Qiu, Q., et al. (2022) Low Lipoprotein(A) Con-centration Is Associated with Atrial Fibrillation: A Large Retrospective Cohort Study. Lipids in Health and Disease, 21, Article No. 119.
https://doi.org/10.1186/s12944-022-01728-5
|
[24]
|
Garg, P.K., Guan, W., Karger, A.B., et al. (2020) Lp(a) (Lipo-protein [A]) and Risk for Incident Atrial Fibrillation: Multi-Ethnic Study of Atherosclerosis. Circulation: Arrhythmia and Electrophysiology, 13, e008401.
https://doi.org/10.1161/CIRCEP.120.008401
|
[25]
|
Moncla, L.M., Briend, M., Bossé, Y., et al. (2020) Calcific Aor-tic Valve Disease: Mechanisms, Prevention and Treatment. Nature Reviews Cardiology, 20, 546-559. https://doi.org/10.1038/s41569-023-00845-7
|
[26]
|
Thomas, P.E., Vedel-Krogh, S., Kamstrup, P.R., et al. (2023) Lipoprotein(A) Is Linked to Atherothrombosis and Aortic Valve Stenosis Independent of C-Reactive Protein. European Heart Journal, 44, 1449-1460.
https://doi.org/10.1093/eurheartj/ehad055
|
[27]
|
Lamina, C. and Kronenberg, F. (2019) Estimation of the Required Lipoprotein(A)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis. JAMA Cardiology, 4, 575-579.
https://doi.org/10.1001/jamacardio.2019.1041
|
[28]
|
Enkhmaa, B., Petersen, K.S., Kris-Etherton, P.M., et al. (2020) Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred By Lp(a)? Nutrients, 12, Article No. 2024. https://doi.org/10.3390/nu12072024
|
[29]
|
Feng, T., Li, Y., Xue, X., et al. (2023) Association of Statin Use and Increase in Lipoprotein(A): A Real-World Database Research. European Journal of Medical Research, 28, Arti-cle No. 212.
https://doi.org/10.1186/s40001-023-01155-x
|
[30]
|
Awad, K., Mikhailidis, D.P., Katsiki, N., et al. (2018) Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(A) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Drugs, 78, 453-462. https://doi.org/10.1007/s40265-018-0870-1
|
[31]
|
Boffa, M.B. and Koschinsky, M.L. (2018) Therapeutic Lowering of Lipoprotein(A): A Role for Pharmacogenetics? Circulation: Genomic and Precision Medicine, 11, e002052. https://doi.org/10.1161/CIRCGEN.118.002052
|
[32]
|
Sahebkar, A., Reiner, Ž., Simental-Mendía, L.E., et al. (2016) Effect of Extended-Release Niacin on Plasma Lipoprotein(A) Levels: A Systematic Review and Meta-Analysis of Ran-domized Placebo-Controlled Trials. Metabolism, 65, 1664-1678. https://doi.org/10.1016/j.metabol.2016.08.007
|
[33]
|
Parish, S., Hopewell, J.C., Hill, M.R., et al. (2018) Impact of Apolipoprotein(A) Isoform Size on Lipoprotein(A) Lowering in the HPS2-THRIVE Study. Circulation: Genomic and Precision Medicine, 11, e001696.
https://doi.org/10.1161/CIRCGEN.117.001696
|
[34]
|
Raschi, E., Casula, M., Cicero, A.F.G., et al. (2023) Beyond Statins: New Pharmacological Targets to Decrease LDL-Cholesterol and Cardiovascular Events. Pharmacology & Ther-apeutics, 250, Article ID: 108507.
https://doi.org/10.1016/j.pharmthera.2023.108507
|
[35]
|
Dawson, L.P., Lum, M., Nerleker, N., et al. (2022) Coro-nary Atherosclerotic Plaque Regression: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 79, 66-82. https://doi.org/10.1016/j.jacc.2021.10.035
|
[36]
|
Ruscica, M., Greco, M.F., Ferri, N., et al. (2020) Lipo-protein(A) and PCSK9 Inhibition: Clinical Evidence. European Heart Journal, 22, L53-L56. https://doi.org/10.1093/eurheartj/suaa135
|
[37]
|
Ostadal, P., Steg, P.G., Poulouin, Y., et al. (2022) Metabolic Risk Factors and Effect of Alirocumab on Cardiovascular Events after Acute Coronary Syndrome: A Post-Hoc Analysis of the ODYSSEY OUTCOMES Randomised Controlled Trial. The Lancet Diabetes & Endocrinology, 10, 330-340. https://doi.org/10.1016/S2213-8587(22)00043-2
|
[38]
|
Kosmas, C.E., Bousvarou, M.D., Papakonstantinou, E.J., et al. (2023) Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(A). International Journal of Molecular Sciences, 24, Article No. 13622.
https://doi.org/10.3390/ijms241713622
|
[39]
|
Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., et al. (2020) Lipoprotein(A) Reduction in Persons with Cardiovascular Disease. The New England Journal of Medicine, 382, 244-255.
https://doi.org/10.1056/NEJMoa1905239
|
[40]
|
Brandts, J. and Ray, K.K. (2023) Novel and Future Li-pid-Modulating Therapies for the Prevention of Cardiovascular Disease. Nature Reviews Cardiology, 20, 600-616. https://doi.org/10.1038/s41569-023-00860-8
|
[41]
|
O’donoghue, M.L., Rosenson, R.S., Gencer, B., et al. (2022) Small Interfering RNA to Reduce Lipoprotein(A) in Cardiovascular Disease. The New England Journal of Medicine, 387, 1855-1864. https://doi.org/10.1056/NEJMoa2211023
|
[42]
|
Wright, R.S., Ray, K.K., Raal, F.J., et al. (2021) Pooled Patient-Level Analysis of Inclisiran Trials in Patients with Familial Hypercholesterolemia or Atherosclerosis. Journal of the American College of Cardiology, 77, 1182-1193.
https://doi.org/10.1016/j.jacc.2020.12.058
|
[43]
|
Ray, K.K., Raal, F.J., Kallend, D.G., et al. (2023) Inclisiran and Cardiovascular Events: A Patient-Level Analysis of Phase III Trials. European Heart Journal, 44, 129-138. https://doi.org/10.1093/eurheartj/ehac594
|